MMP19 and heart failure: In our study, the up-titration of all four pillars of GDMT was successfully achieved across all heart failure risk groups, whereby 73%, 75%, 62%, 86%, and 45% of patients received ≥90% of TDs of BB, RASi, MRA, SGLT2i, and triple-therapy, respectively.